Peptide LexiconAll compounds

VK2735: Viking Therapeutics' GLP-1/GIP Dual-Agonist Peptide — What It Is, What the 13-Week VENTURE Trial Showed and What Is Still in Phase 3

VK2735 is an investigational peptide from Viking Therapeutics that activates both GLP-1 and GIP receptors, the same pairing as tirzepatide. In the published 13-week phase 2 VENTURE trial of a weekly injection, mean weight loss ran from 9.1% to 14.7% against 1.7% on placebo. It is not approved anywhere; phase 3 trials of injectable and oral forms are under way.

Investigational — not approvedGLP-1/GIP receptor dual agonistPhase 3 (injectable and oral)

Caroline S · Published 2026-11-20

Length

Not published in the sources opened; PubChem held no record for VK2735 on 2026-11-20

Sequence

Not published in the sources opened. The VENTURE paper describes a peptide incorporating both incretin activities, with a side chain that extends its half-life

Origin

Viking Therapeutics (San Diego). Developed as a weekly subcutaneous injection and a once-daily oral tablet (ClinicalTrials.gov)

Last reviewed

2026-11-20

What is it good for?

It is being tested for weight management in adults with obesity, or overweight with a weight-related condition, with and without type 2 diabetes. It has no approved use. The one published efficacy trial is a 13-week dose-finding study of a weekly injection in adults without diabetes.

Illustration: A glass measuring cylinder with a copper rim holding green liquid on a white surface.
Illustration

What it is

VK2735 is an investigational peptide that switches on two incretin receptors at once — GLP-1 and GIP — and it has no approved use anywhere. Its developer, Viking Therapeutics, is testing it for weight management. The one peer-reviewed efficacy paper (Bays 2026, Obesity, written by trial investigators with Viking authors) describes it as a GLP-1/GIP receptor dual agonist and says the peptide "incorporates the activities of both incretins and contains a side chain that imparts an extended half-life" when injected under the skin.

Property Value Source
Class GLP-1/GIP receptor dual agonist peptide VENTURE paper
Amino-acid sequence Not published in the sources opened PubChem: no record (2026-11-20)
Half-life feature A side chain that extends half-life VENTURE paper
Forms in trials Weekly subcutaneous; once-daily oral ClinicalTrials.gov
Status Investigational, phase 3 ClinicalTrials.gov

How it acts. GLP-1 and GIP are hormones released by the gut after eating that raise insulin and, in the case of GLP-1, slow the stomach and reduce appetite; the library's GLP-1 and GIP entries explain each. The approved drug with the same GLP-1/GIP pairing is tirzepatide, which the VENTURE paper cites as its reference point. Other trial-stage incretin peptides in the library take different pairings — retatrutide adds the glucagon receptor, and survodutide and mazdutide pair GLP-1 with glucagon.

What the human evidence amounts to: one published phase 2 trial lasting 13 weeks, in adults without diabetes, sponsored by the developer. There is no published phase 3 result, no long-term data and no independent pharmacology paper in PubMed.

What the trial showed

VENTURE (NCT06068946) was a phase 2, randomised, double-blind, placebo-controlled dose-finding study run between August 2023 and February 2024. It enrolled adults with obesity, or overweight with at least one weight-related condition; people with diabetes were not eligible. The primary end point was percentage weight change at week 13.

Weekly dose Mean weight change at week 13 Source
Placebo −1.8 kg (−1.7%) PMID 41508550
2.5 mg (lowest) −9.2 kg (−9.1%) PMID 41508550
15 mg (highest) −14.6 kg (−14.7%) PMID 41508550

Across all active doses, 93% (130 of 140) lost at least 5% of their starting weight, against 12% (4 of 34) on placebo.

Tolerability, from the full text. Drug-related nausea was reported by 64 of 175 treated participants and vomiting by 22 of 175 — 36.6% and 12.6% by this entry's arithmetic. Of 176 participants, 24 (14%) stopped treatment early, 15 (8.5%) of them because of adverse events. The paper reports that gastrointestinal effects became less frequent after dose titration reached steady state, and lists 12 serious adverse events in 8 participants, of which 2, in the same participant, were judged possibly or probably related (atrial fibrillation and dehydration). One death, from head trauma after a fall, was judged unrelated.

What 13 weeks cannot show: where weight loss levels off, whether it is kept, and how the drug compares with approved treatments. The trials designed to answer the first two are the 78-week phase 3 studies below.

Where it stands

No regulator has approved VK2735; Drugs@FDA and openFDA held no record of it on 2026-11-20. ClinicalTrials.gov listed eight studies that day:

Trial Phase Form Planned size Status
NCT05203237 1 — 92 Completed
NCT06068946 (VENTURE) 2 Weekly injection 176 Completed
NCT06828055 (VENTURE-Oral) 2 Daily tablet 280 Completed (primary completion 2025-06-24)
NCT07104500 3 Weekly injection, 78 weeks, no diabetes 4,500 Active, not recruiting
NCT07104383 3 Weekly injection, type 2 diabetes 1,100 Active, not recruiting
NCT07868835 (SUNRISE 1) 3 Daily tablet 560 Recruiting
NCT07868939 3 Daily tablet, type 2 diabetes 560 Recruiting
NCT07838740 1 — 270 Recruiting

The oral phase 2 trial is listed as completed, but this entry found no peer-reviewed results for it in PubMed and does not report figures from it. Weight-loss medicines that are approved, and the question of which suits whom, are covered by GLP-1 Ledger; this library describes the compound.

Sources opened 2026-11-20: Bays 2026, Obesity (VENTURE, PMID 41508550, abstract; full text PMC12933218 for the mechanism description, discontinuations and adverse events); ClinicalTrials.gov API v2 (8 VK2735 studies; NCT06828055 and NCT07104500 records); PubMed E-utilities (2 records); PubChem name search (no record); openFDA and Drugs@FDA (no record).

What the research shows

Weekly injection lowers body weight over 13 weeks

VENTURE phase 2 (Bays 2026, Obesity, PMID 41508550; NCT06068946): 176 participants; mean weight change −9.1% (2.5 mg) to −14.7% (15 mg) v −1.7% on placebo

Oral tablet lowers body weight

VENTURE-Oral phase 2 (NCT06828055, 280 participants, 13 weeks) is listed as completed; no peer-reviewed results were found in PubMed on 2026-11-20

Activates GLP-1 and GIP receptors

Described by the sponsor's investigators in the VENTURE paper; no independent pharmacology paper was found in PubMed

Bars show how much of the evidence is in humans, not how well anything works.

Where it stands

Regulatory

Investigational; not approved by the FDA or any other regulator in the sources opened. Drugs@FDA and openFDA held no record on 2026-11-20.

Trials

ClinicalTrials.gov lists 8 studies (2026-11-20): phase 1 ×2, phase 2 ×2 (both completed), and phase 3 ×4 — VANQUISH-type 78-week injectable trials (NCT07104500, 4,500 planned; NCT07104383, 1,100 planned, type 2 diabetes) and oral SUNRISE trials (NCT07868835, NCT07868939, 560 each).

Published record

PubMed: 2 records for 'VK2735' — the VENTURE paper and a 2026 review (2026-11-20).

Frequently asked questions

What is VK2735?

An investigational peptide from Viking Therapeutics that activates two gut-hormone receptors, GLP-1 and GIP. It is being tested for weight management as a weekly injection and as a daily tablet. It is not approved.

How is VK2735 related to tirzepatide?

Both activate GLP-1 and GIP receptors, and the VENTURE paper places VK2735 beside tirzepatide, which is approved for type 2 diabetes and obesity. VK2735's own structure has not been published in the sources this entry opened, and no trial has compared the two directly.

How much weight did people lose in the trial?

In the 13-week VENTURE trial, mean weight loss ranged from 9.1% on the 2.5 mg weekly dose to 14.7% on 15 mg, against 1.7% on placebo. 93% of people on any active dose lost at least 5% of their weight, against 12% on placebo.

What doses were tested?

VENTURE tested weekly subcutaneous doses from 2.5 mg to 15 mg against placebo for 13 weeks. These are trial doses in a dose-finding study, not an approved regimen; no regulator has set a dose.

What side effects were reported?

Mostly gastrointestinal. Drug-related nausea was reported by 36.6% and vomiting by 12.6% of treated participants, and 8.5% stopped early because of adverse events. The paper reports that gastrointestinal effects became less frequent after the dose had been stepped up to steady state.

When could VK2735 be approved?

This entry does not forecast it. ClinicalTrials.gov lists phase 3 trials that began in 2025, with the largest injectable trial giving a primary completion date of July 2027.